Benjamin Gudorf
Family · Rockford, OHNPI 1740704857
Payments from drug & device makers
Across 251 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$643
- AstraZeneca$604
- Abbott$535
- AbbVie$493
- Amgen$354
- Sanofi-aventis U.S. LLC$167
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,28099%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $643 |
| AstraZeneca | 31 | $604 |
| Abbott | 29 | $535 |
| AbbVie | 28 | $493 |
| Amgen | 22 | $354 |
| Sanofi-aventis U.S. LLC | 12 | $167 |
| Lilly USA, LLC | 10 | $163 |
| Insulet Corporation | 6 | $161 |
| Exact Sciences | 8 | $140 |
| Boehringer Ingelheim | 9 | $137 |
| GSK | 7 | $117 |
| Medtronic | 5 | $87 |
| Bayer | 5 | $84 |
| Nestle Healthcare Nutrition Inc. | 4 | $72 |
| Corium, LLC | 4 | $71 |
| Tandem Diabetes Care, Inc. | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Organogenesis Inc. | 1 | $58 |
| Dexcom, Inc. | 3 | $53 |
| Astellas Pharma US Inc | 3 | $44 |
| Novartis | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
How this compares
$4,313 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $91,442 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $90,964 |
| TrulicityDulaglutide | 51 | $69,427 |
| EliquisApixaban | 38 | $53,341 |
| JardianceEmpagliflozin | 38 | $51,083 |
| MounjaroTirzepatide | 40 | $49,821 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 41 | $36,779 |
| Repatha SureclickEvolocumab | 19 | $28,515 |
| RybelsusSemaglutide | 11 | $20,884 |
| FarxigaDapagliflozin Propanediol | 23 | $20,565 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $15,849 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,082 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,238 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $7,316 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 118 | $2,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $163 | $119,24891 claims |
| Novo NordiskOzempic, Rybelsus | $643 | $112,32667 claims |
| PfizerEliquis | $13 | $53,34138 claims |
| Boehringer IngelheimJardiance | $137 | $51,08338 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $167 | $36,77941 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $604 | $36,41448 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $117 | $28,63662 claims |
| AbbVieSynthroid | $493 | $1,28160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Rockford
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.